This page shows the latest Alecensa news and features for those working in and with pharma, biotech and healthcare.
Sales of Xalkori have come under pressure recently as it faces increasing pressure from Roche’s Alecensa (alectinib) and Novartis’ Zykadia (ceritinib), with both therapies having previously bested Pfizer’s ... Although Lorbrena will face extreme
In Europe, sales were down 1% thanks to the competition from biosimilars for Herception and Rituxan, but there was growth reported in the uptake of Ocrevus, Perjeta, Tecentriq, Alecensa and Hemlibra.
Alecensa (alectinib), Novartis’ Zykadia (ceritinib), and Takeda’s Alunbrig (brigatinib).
Roche’s Alecensa (alectinib), Novartis’ Zykadia (ceritinib), and Takeda’s Alunbrig (brigatinib).
Lorbrena can also be used in patients who have seen disease progression on Roche’s Alecensa and Novartis’ Zykadia.
However, the performance of Ocrevus and other drugs such as HER2 breast cancer therapy Perjeta (pertuzumab) and lung cancer therapy Alecensa (alectinib) – plus a strong showing in Asia-Pacific markets led
More from news
Approximately 16 fully matching, plus 23 partially matching documents found.
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....